Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

600
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
600
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
204
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

149
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
149
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

704
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
704
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

351
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
351

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diblock Copolymer Engineered Swim Bladder Membrane Enables Spatiotemporal Synchronized Defense and Pro-Healing in Challenging Soft Tissue Regeneration.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Tailoring Interfaces With Poly(Ionic Liquid)-Grafted Porous Hybrid Molecular Brushes in Quasi-Solid-State Composite Electrolytes Enables Ultrahigh-Rate and High-Voltage Lithium Metal Batteries.

Angewandte Chemie (International ed. in English)·2026
Same author

Third-Component-Regulated Choline Chloride-Monoethanolamine-Based Solvent Systems for Enhanced Valorization of Bamboo Toward Concurrent Bioethanol and Carbon Dot Production.

Molecules (Basel, Switzerland)·2026
Same author

Polarization control enabled by on-chip three-dimensional rotator.

Fundamental research·2026
Same author

Responses of Methane Emissions to Different Soil Amendments in Paddy Soil: Soil Properties, Microbial Communities, and Functional Genes.

Biology·2026
Same author

Comparative efficacy of exercise interventions on depressive symptoms and related outcomes in patients with Alzheimer's disease, cognitive impairment, and Parkinson's disease: a systematic review and network meta-analysis.

Frontiers in physiology·2026
Same journal

Reassessing the Proposed Creatine-PrP Axis in Endometriosis: Methodological and Mechanistic Considerations.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

IL-7R-Enriched Extracellular Vesicles From the Thymus Drive Colitis via Promoting Neutrophil Extracellular Trap Formation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Systematic Phosphorus-Driven Structural and Field Engineering of n-a-Si:H for Flexible n-a-Si:H/Te Near-Infrared Photodetectors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Chemically Gradient Ordered Nanodomains Enable Large Tensile Ductility in Gigapascal Lightweight Refractory High-Entropy Alloys.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Single-Molecule Characterization of Bacterial Factor-Dependent Transcription Activation by Rob.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

919

Probiotic-Enhanced Porous Bio-Hybrids with Inflammatory Targeting, ROS Scavenging, and Long-Term Drug Release for

Luna Quan1, Yang Ouyang2, Weiwen Liang2

  • 1PCFM Lab, School of Chemistry, Sun Yat-sen University, Guangzhou, 510006, P. R. China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|June 27, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed a novel probiotic-enhanced porous bio-hybrid (E-xPAM@ASA) for targeted intestinal inflammation treatment. This material effectively delivers drugs, scavenges reactive oxygen species, and improves therapeutic outcomes in colitis models.

Keywords:
ROS scavenginghyper‐cross‐linking polymersinflammatory targetinglong‐term drug releaseulcerative colitis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

Related Experiment Videos

Last Updated: Sep 17, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

919
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

Area of Science:

  • Biomaterials Science
  • Gastroenterology
  • Nanotechnology

Background:

  • Functional porous materials offer high surface area and tunable pore structures for biomedical uses.
  • The gastrointestinal environment presents challenges for nanomaterial targeting and controlled drug release.
  • Inflammatory bowel diseases require advanced therapeutic platforms for effective treatment.

Purpose of the Study:

  • To design and synthesize a novel probiotic-enhanced porous bio-hybrid material (E-xPAM@ASA) for targeted intestinal inflammation therapy.
  • To evaluate the drug loading, release, and reactive oxygen species scavenging capabilities of the designed material.
  • To assess the therapeutic efficacy of E-xPAM@ASA in a preclinical model of ulcerative colitis.

Main Methods:

  • Bio-hybridization of 5-aminosalicylic acid-loaded microporous nanospheres (xPAM@ASA) with probiotic Escherichia coli Nissle 1917 (EcN).
  • Characterization of the porous structure, drug loading, and release kinetics of E-xPAM@ASA.
  • Evaluation of reactive oxygen species scavenging activity.
  • Assessment of therapeutic effects in a dextran sulfate sodium-induced ulcerative colitis murine model, including mucosal repair, inflammation markers, and microbiota analysis.

Main Results:

  • The E-xPAM@ASA demonstrated enhanced accumulation in intestinal inflammatory sites due to EcN's targeting ability.
  • The porous nanospheres facilitated high drug loading, sustained release, and effective reactive oxygen species scavenging.
  • In the colitis model, E-xPAM@ASA significantly promoted mucosal repair, alleviated inflammation, and regulated gut microbiota.

Conclusions:

  • The developed probiotic-enhanced porous bio-hybrid (E-xPAM@ASA) shows significant potential as a multifunctional therapeutic platform.
  • This approach offers a promising strategy for precise and effective treatment of intestinal inflammation.
  • The study highlights the synergy between probiotics and porous nanomaterials for advanced biomedical applications.